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Condensation 
Femur-sparing pattern of fetal growth restriction following maternal Zika virus infection 
with smaller head and abdominal circumference in relation to femur length. 
Short Version of the Title 
Femur-sparing pattern of fetal growth restriction after Zika virus infection 
Implications and Contributions  
A. Why was this study conducted? 
To determine if Zika virus infection during pregnancy is associated with a femur-sparing 
pattern of fetal growth restriction, similar to observations in a nonhuman primate model 
of decelerating growth of the fetal head and abdomen with respect to femur length.  
B. What are the key findings? 
An unusual femur-sparing pattern of fetal growth restriction was detected in the majority 
of fetuses with congenital ZIKV exposure using Intergrowth-21st Project fetal body ratios 
comparing head or abdominal circumference to femur length. 
C. What does this study add to what is already known? 
Fetal body ratios may provide a new screening tool to detect Zika virus-associated fetal 
injury in pregnancies without overt microcephaly. 
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Abstract: 
Background: Zika virus (ZIKV) is a mosquito-transmitted flavivirus, which can induce 
fetal brain injury and growth restriction following maternal infection during pregnancy. 
Prenatal diagnosis of ZIKV-associated fetal injury in the absence of microcephaly is 
challenging due to an incomplete understanding of how maternal ZIKV infection affects 
fetal growth and the use of different sonographic reference standards around the world. 
We hypothesized that skeletal growth is unaffected by ZIKV infection and that the femur 
length can represent an internal standard to detect growth deceleration of the fetal head 
and/or abdomen by ultrasound.  
Objective: To determine if maternal ZIKV infection is associated with a femur-sparing 
pattern of intrauterine growth restriction (IUGR) through analysis of fetal biometric 
measures and/or body ratios using the INTERGROWTH-21st Project (IG-21) and World 
Health Organization Fetal Growth Chart (WHO-FGC) sonographic references. 
Study Design: Pregnant women diagnosed with a possible recent ZIKV infection at 
Columbia University Medical Center after traveling to an endemic area were 
retrospectively identified and included if a fetal ultrasound was performed. Data was 
collected regarding ZIKV testing, fetal biometry, pregnancy and neonatal outcomes. The 
IG-21 and WHO-FGC sonographic standards were applied to obtain Z-scores and/or 
percentiles for fetal head, abdominal circumference (HC, AC) and femur length (FL) 
specific for each gestational week. A novel IG-21 standard was also developed to 
generate Z-scores for fetal body ratios with respect to femur length (HC:FL, AC:FL). 
Data was then grouped within clinically relevant gestational age strata (<24 weeks, 24-
27 6/7, 28-33 6/7, >34 weeks) to analyze time-dependent effects of ZIKV infection on 
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fetal size. Statistical analysis was performed using Wilcoxon signed-rank test on paired 
data, comparing either AC or HC to FL. 
Results: A total of 56 pregnant women were included in the study with laboratory 
evidence of a confirmed or possible recent ZIKV infection. Based on the CDC definition 
for microcephaly after congenital ZIKV exposure, microcephaly was diagnosed in 5% 
(3/56) by both the IG-21 and WHO-FGC standards (HC Z-score ≤ -2 or ≤ 2.3%). Using 
IG-21, IUGR was diagnosed in 18% of pregnancies (10/56; AC Z-score ≤-1.3, <10%). 
Analysis of fetal size using the last ultrasound scan for all subjects revealed a 
significantly abnormal skewing of fetal biometrics with a smaller AC versus FL by either 
IG-21 or WHO-FGC (p<0.001 for both). A difference in distribution of fetal AC compared 
to FL was first apparent in the 24-27 6/7 week strata (IG-21, p=0.002; WHO-FGC, 
p=0.001). A significantly smaller HC compared to FL was also observed by IG-21 as 
early as the 28-33 6/7 week strata (IG-21, p=0.007). Overall, a femur-sparing pattern of 
growth restriction was detected in 52% of pregnancies with either an HC:FL or AC:FL 
fetal body ratio less than the 10th percentile (IG-21 Z-score ≤-1.3).  
Conclusions: An unusual femur-sparing pattern of fetal growth restriction was detected 
in the majority of fetuses with congenital ZIKV exposure. Fetal body ratios may 
represent a more sensitive ultrasound biomarker to detect viral injury in 
nonmicrocephalic fetuses that could impart long-term risk for complications of 
congenital ZIKV infection.  
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Glossary of Terms 
AC, abdominal circumference 
BPD, biparietal diameter 
CDC, Centers of Disease Control 
FL, femoral length 
HC, head circumference 
IG-21, 2014 International Fetal and Newborn Growth Consortium for the 21st Century 
IUGR, intrauterine fetal growth restriction 
NICHD, Eunice Kennedy Shriver National Institute of Child Health and Development 
PRNT, plaque reduction neutralization test 
RT-PCR, real-time polymerase chain reaction testing 
WHO, World Health Organization 
WHO-FGC, World Health Organization Fetal Growth Chart 
ZIKV, Zika virus  
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Introduction 1 
Zika virus (ZIKV) is a mosquito-transmitted flavivirus, recently linked to microcephaly 2 
following a maternal infection during pregnancy.[1] Vertical transmission of ZIKV has 3 
been associated with fetal microcephaly and development of the Congenital ZIKV 4 
Syndrome, a condition encompassing a spectrum of fetal neurologic injury including 5 
cortical malformations, ventriculomegaly, ocular injury and arthrogryposis.[2, 3, 4] A 6 
maternal ZIKV infection has been associated with a rate of birth defects between 5-8%, 7 
but may be as high as 13% when infection occurs in the first trimester.[5, 6] Recently, 8 
reports of children with a normal head circumference (HC) at birth that were later found 9 
to have abnormal brain imaging, ocular injury and postnatal development of 10 
microcephaly, has led to the concept that microcephaly does not capture the broader 11 
spectrum of ZIKV-associated brain injury.[3, 7, 8, 9, 10] Identification of fetuses with a 12 
normal head size that are at risk for long-term adverse outcomes remains limited due to 13 
the incomplete knowledge of how a less overt spectrum of ZIKV-associated fetal injury 14 
may be detected prenatally. This limitation is further compounded by weaknesses 15 
related to diagnostic testing including: 1) inadequate availability of ZIKV testing in 16 
regions at risk, 2) lower sensitivity of real-time polymerase chain reaction testing (RT-17 
PCR) due to the transient nature of ZIKV viremia, and 3) lower positive predictive value 18 
of serologic testing due to cross-reactivity between ZIKV and related flaviviruses. 19 
In a nonhuman primate model, ZIKV-associated fetal brain injury was associated with 20 
an unusual femur-sparing profile of intrauterine growth restriction (IUGR) notable for a 21 
growth arrest in ultrasound biometric measures of the fetal head (biparietal diameter, 22 
BPD) and abdomen (abdominal circumference, AC) with continued growth of the femur 23 
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(femur length, FL).[11, 12] This profile of IUGR has been noted as “femur-sparing”[13], 24 
but has not been characterized in a clinical study nor is it part of the mainstream 25 
categories for IUGR; typically, IUGR has been defined as asymmetric (conserved head 26 
growth with lagging growth of the abdomen) or symmetric (equal growth restriction of 27 
the head, abdomen and femur).[14]  28 
There is a paucity of data to link aberrant fetal growth in the context of a maternal ZIKV 29 
infection to long-term adverse outcomes in the neonate, but IUGR may represent a 30 
sensitive indicator of viral injury to the placenta or fetus itself. Whether fetuses exposed 31 
to Zika virus with abnormal growth patterns, without microcephaly, may be more 32 
susceptible to eye injury or late-onset microcephaly is unknown and represents an 33 
important knowledge gap.[15] Although IUGR has been reported in pregnant women 34 
with a possible ZIKV infection, the profile of IUGR has not been described.[10, 16] Our 35 
objective was to determine if maternal ZIKV infection was associated with a femur-36 
sparing profile of growth restriction, similar to observations in a nonhuman primate 37 
model of congenital ZIKV infection.[11, 12] Such an observation may be a first step in 38 
identifying nonmicrocephalic fetuses at risk for long-term morbidity.  39 
 40 
Materials and Methods 41 
Study Population and Ethics Statement 42 
All pregnant women presenting to Columbia University Medical Center from January 1, 43 
2016 through February 1, 2017 from an area with known ZIKV local transmission were 44 
offered screening per Centers of Disease Control (CDC) recommendations. The 45 
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Columbia University Institutional Review Board approved the study (IRB-AAAQ9686) as 46 
a retrospective chart review and informed consent was not required. Cases were 47 
excluded if no ultrasound for fetal size or anatomy was completed prior to delivery. The 48 
gestational age and due date were estimated according to methods recommended by 49 
the American College of Obstetricians and Gynecologists.[17] Following ZIKV 50 
diagnosis, a pregnancy ultrasound was performed, and repeated every 3-4 weeks, for 51 
the duration of the pregnancy. Timing of ZIKV exposure was estimated based on 52 
maternal travel history, but could have occurred later in pregnancy due to sexual 53 
exposure from an infected partner; therefore, we included 4 subjects with immediate 54 
pre-conception exposure (Table S4). Neonatal outcomes were assessed through 55 
measurement of a postnatal HC and head ultrasound scan in the first week of life. A 56 
more comprehensive assessment of outcomes was not possible due to limitations on 57 
our institutional human subject’s approval and the challenge of data procurement from 58 
multiple private pediatric clinics in New York City; therefore, results for some 59 
recommended neonatal screening tests were not obtained. 60 
ZIKV Diagnosis 61 
Based on uncertainties in the diagnostic testing for ZIKV infection, we followed CDC 62 
convention to describe women as having a “possible” ZIKV infection based on: 1) ZIKV 63 
infection detected by ribonucleic acid (RNA) testing on maternal, placental or fetal 64 
specimen, or 2) diagnosis of ZIKV infection or unspecified flavivirus infection, timing of 65 
infection cannot be determined (i.e., positive/equivocal ZIKV IgM and ZIKV plaque 66 
reduction neutralization test (PRNT) titer ≥ 10, regardless of dengue virus PRNT value; 67 
or negative ZIKV IgM, and positive or equivocal dengue virus IgM, and ZIKV PRNT titer 68 
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≥ 10, regardless of dengue virus PRNT titer).[18, 19] We also followed CDC guidance 69 
for the interpretation of laboratory testing of the infant for evidence of congenital ZIKV 70 
infection.[18] Any positive nucleic acid test from a serum, urine or cerebrospinal fluid 71 
sample was considered a confirmed congenital ZIKV infection. Any non-negative IgM 72 
result (e.g. positive, equivocal) from infant serum with a negative nucleic acid test was 73 
considered a probable congenital ZIKV infection. 74 
Ultrasound Methodology 75 
The INTERGROWTH-21st (IG-21) sonographic standard was used to derive Z-scores 76 
for HC, AC and FL, as well as ratios for HC:FL and AC:FL.[20, 21, 22] Ultrasound scans 77 
were originally performed using Hadlock methodology, which measures BPD in a cross-78 
section view from outer-to-inner skull edges. As IG-21 measures the BPD from outer-to-79 
outer skull edges, BPD measurements in this study were not directly translatable to the 80 
IG-21 sonographic standard. We chose instead to focus the analysis on HC, AC and FL 81 
measurements from which we could directly calculate Z-scores. As the sonographic 82 
standard or reference used to interpret fetal size is expected to influence detection of 83 
IUGR in pregnancies with maternal ZIKV infection, we also corroborated the findings by 84 
applying references from the WHO sponsored Fetal Growth Chart study (WHO-85 
FGC).[20, 23] 86 
Online calculators were used to obtain Z-scores for IG-21[22] and published charts 87 
allowed estimation of percentiles for WHO-FGC.[20, 23] Notably, the WHO 88 
recommends that diagnosis of ZIKV-associated microcephaly use the IG-21 standard 89 
when the gestational age is accurately known and WHO-FGC when gestational age is 90 
not reliably known.[24] Studies of pregnancy outcomes from Brazilian women with ZIKV 91 
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infection have also used the IG-21 standard to determine distribution of fetal biometric 92 
measures.[9, 25, 26]  93 
We did not evaluate our data based on sonographic standards developed in the U.S. for 94 
two reasons. First, the 1983 Hadlock standard (N=392) was based on a relatively small 95 
cohort of Caucasian women and has anecdotally been associated with a common 96 
diagnosis of “short femur”.[27, 28, 29, 30] Second, application of racial/ethnic specific 97 
standards based on the NICHD Fetal Growth Study (N=2,334)[31] would only have 98 
allowed for assignment of biometric measures within ranges of centiles (i.e.. <3rd, 3rd – 99 
5th, 5th-10th), but not a more precise and quantitative analysis necessary to test our 100 
hypothesis. Our data on subject ethnicity was also incomplete. We ultimately chose to 101 
compare our data to the IG-21 and WHO-FGC standards as they were large population-102 
based studies from multiple countries that included an ethnically diverse cohort. 103 
Notably, we could also use the IG-21 standard to specifically test our hypothesis of a 104 
femur-sparing profile of fetal growth restriction using fetal body ratios. 105 
Definitions for Microcephaly and IUGR 106 
Variations in the definition for prenatal diagnosis of microcephaly with possible ZIKV 107 
infection exist among guidelines and standards.[10, 32, 33] The International Society for 108 
Ultrasound in Obstetrics & Gynecology recommends heightened surveillance with 109 
specialist referral and neurosonography for fetuses with a HC smaller than 2 standard 110 
deviations below the mean (Z-score ≤ -2 SD).[34] The WHO definition for fetal 111 
microcephaly, in the context of ZIKV infection, is a HC ≤ -2 SD below the mean.[33] 112 
After birth, the CDC definition for microcephaly is a HC less than the 3rd centile for 113 
gestational age in the setting of congenital ZIKV exposure (≤ -2 SD).[35] Based on this 114 
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guidance, we defined microcephaly in our study as a fetal HC Z score ≤ -2 (2.3%, IG-115 
21) or less than the 3rd centile (WHO-FGC). 116 
There is no gold standard to define IUGR and it has been variably defined by deviation 117 
of fetal size from a normal distribution at either the 10th, 5th or 3rd centile.[36, 37] The 118 
estimated fetal weight (EFW) and AC are consistently identified as important 119 
parameters in making the diagnosis and a typical threshold is less than the 10th centile; 120 
however, this definition will include many constitutionally small fetuses and miss growth 121 
restricted fetuses that are larger than the 10th centile.[38] In this study, we present 122 
results using both a conservative (AC <3%, ~Z score ≤ -2) and traditional (AC <10%, ~Z 123 
score ≤ -1.3) definition for IUGR to allow comparison of results with AC:FL, a fetal body 124 
ratio for AC normalized to FL. Due to the difference in BPD measurements between 125 
Hadlock and IG-21, BPD could not be used to calculate EFW; therefore, EFW was not 126 
used as a measure of IUGR in this study.  127 
Estimating Population Distribution of Fetal Body Ratios 128 
Fetal body ratios normalized to FL were hypothesized to represent a more sensitive 129 
method to detect aberrant growth patterns in fetuses with congenital ZIKV exposure. 130 
This approach has the advantage of directly addressing our hypothesis by comparing 131 
the size of fetal structures (i.e. head, abdomen) to FL for each fetus, but may not detect 132 
constitutionally small fetuses and fetuses with symmetric IUGR. The WHO-FGC has 133 
published ratios for FL:HC, but values often overlapped several strata making it difficult 134 
to categorize some cases into discrete strata.[20] Therefore, we focused attention on 135 
the IG-21 standard from which we could calculate Z-scores for HC:FL and AC:FL. 136 
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Published thresholds for IG-21 body ratios did not exist; therefore, we developed these 137 
formulas, including mean and standard deviations from the original data (means and 138 
standard deviations by gestational week shown in Tables S1, S2, S3). Statistical 139 
methods used to construct the fetal biometry ratios were selected using a previously 140 
published strategy.[21, 39] In brief, fractional polynomial regression was used, and the 141 
resulting functional form further modelled in a multi-level framework to account for the 142 
longitudinal design of the study. Goodness-of-fit was evaluated with visual inspection of 143 
overall model fit using quantile-quantile plots of the residuals, plots of residual versus 144 
fitted values and the distribution of fitted Z-scores across gestational age. All models 145 
and goodness-of-fit assessments were fitted with STATA, version 11.2, software 146 
(StataCorp LP, College Station, Texas, USA).   147 
Statistical Analysis 148 
Raw measurements for all biometric measures were recorded in millimeters (mm). We 149 
analyzed the data in clinically relevant gestational age strata for two reasons: 1) 150 
identifying a gestational age threshold at which ZIKV-associated abnormal fetal growth 151 
is typically observed has clinical relevance and 2) the effects of ZIKV infection on fetal 152 
growth are likely time-dependent with more significant effects occurring in later 153 
pregnancy. Gestational age strata were chosen to correspond to transitions classically 154 
associated with neonatal viability (18-24 weeks) and morbidity (late second trimester: 155 
24-28 weeks, early third trimester: 28-34 weeks, and near term ≥ 34 weeks). The latest 156 
ultrasound per subject was analyzed in each gestational age strata. Wilcoxon signed 157 
rank test was used to compare distribution of paired Z-scores for HC to FL or AC to FL. 158 
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Statistical significance was reported for p values <0.05. Analysis was completed using 159 
STATA version 11.2, software (StataCorp LP, College Station, Texas, USA). 160 
Results 161 
ZIKV Diagnosis and Timing of Exposure 162 
Study participants were pregnant women diagnosed with ZIKV infection after travel to 163 
countries with local transmission, who received obstetrical care from Columbia 164 
University Medical Center (New York City, NY, USA) between January 1, 2016 and 165 
February 1, 2017. A total of 66 pregnant women were retrospectively identified with a 166 
recent ZIKV infection and 56 were included based on availability of ultrasound data 167 
within the Columbia University health care system. The cohort was of mixed 168 
race/ethnicity: 12 Hispanic/White, 7 Hispanic/Black, 2 Hispanic/Pacific Islander, 3 White, 169 
and 32 other (unknown/more than one race). Thirteen women (13/56, 23%) recalled 170 
symptoms consistent with ZIKV infection including a rash, conjunctivitis, fever and 171 
myalgias (Table S4). ZIKV infection was diagnosed based on laboratory evidence for a 172 
confirmed ZIKV infection (N=21) or unspecified flavivirus infection (N=35; Table S4) 173 
according to the U.S. Zika Pregnancy Registry criteria.[5, 40] By travel history, ZIKV 174 
exposure was estimated to have occurred immediately preconception (N=4) or in the 175 
first (N=16) or second trimester (N=11). An additional 25 women were more uncertain of 176 
exposure timing due to prolonged stays in endemic areas and presented to care in the 177 
late second or third trimester (mean 30.8 ± 4.5 weeks).  178 
Pregnancy and Birth Outcomes 179 
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Prenatal ultrasound was performed between 14 and 40 weeks gestation with each 180 
subject typically having 3 ultrasound scans [range 1-7; ≥ 3 scans, N=29 (52%); 2 scans, 181 
N= 15 (27%); 1 ultrasound, N=12 (21%)]. During pregnancy, microcephaly was 182 
diagnosed in 5% (3/56) of fetuses by both the IG-21 (HC Z-score ≤ -2) and WHO-FGC 183 
(≤ 3rd centile; Table S5). Apart from isolated choroid plexus cysts, no other intracranial 184 
abnormalities were detected on prenatal ultrasound. IUGR was diagnosed in 18% of 185 
pregnancies by a traditional definition (10/56; AC Z-score ≤-1.3, <10th centile) and 9% 186 
by a conservative definition (5/56; AC Z-score ≤-2 or ≤ 2.3 centile, Table 1) using IG-21 187 
standards. The mean Z-score for birthweight for the entire cohort was 0.2 ± 1.0.  188 
Pregnancy outcomes were available in 52 of 56 cases (Table S6). In three pregnancies 189 
(3/52; 6%), a pregnancy termination was performed in the second trimester after a 190 
diagnosis of microcephaly. One stillbirth occurred at 30 weeks gestation (1/52; 2%) in a 191 
microcephalic fetus with symmetric severe growth restriction. Of the remaining 48 192 
pregnancies, term birth occurred in 92% (44/48) and preterm birth in 8% (4/48). A 193 
postnatal head ultrasound was performed in 39 cases and identified a grade 1 194 
intraventricular hemorrhage (1/39, 3%) or choroid plexus cyst (4/39, 10%), but no other 195 
structural findings associated with the congenital ZIKV syndrome (Table S6). Neonatal 196 
HC was measured in 47 of the 48 newborns with a mean Z-score of 0.4 using IG-21. At 197 
birth, microcephaly was observed in one neonate (HC Z-score ≤ -2) and no neonates 198 
had a HC Z-score ≤ -3 (Table S6). Interpretation of the laboratory testing for ZIKV 199 
infection of the neonate is limited by the transient nature of the viremia, but results were 200 
available for 41 infants; a possible ZIKV infection was diagnosed in 39% of cases 201 
(16/41, Table S4) and one infant had a confirmed ZIKV infection (1/41, 2%). 202 
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Microcephaly and Femur-Sparing Pattern of IUGR Identified using Single Fetal 203 
Biometric Measures and Fetal Body Ratios 204 
Next, we compared paired biometric measures from each subject to determine if 205 
maternal ZIKV infection was associated with differential growth of the HC or AC with 206 
respect to the FL. Overall, the AC was significantly smaller than FL based on the last 207 
ultrasound scan in pregnancy by either IG-21 or WHO-FGC (Tables 2 and S7, p<0.001 208 
for both analyses); this difference was also significant in every strata starting with the 209 
24-27 6/7 week category for IG-21 and most strata for WHO-FGC. The HC was also 210 
significantly smaller than FL in the overall analysis by IG-21 (p<0.001) and in every 211 
strata beginning with 28-33 6/7 weeks; this difference was not significant by WHO-FGC. 212 
Another method to identify ZIKV-associated differential growth of the fetal head or 213 
abdomen with respect to the femur would involve an analysis of fetal body ratios (e.g. 214 
HC:FL or AC:FL). To this end, we developed IG-21 fetal body ratios based on 215 
previously published data from 4,607 normal pregnancies in 18 different countries.[21] 216 
These fetal body ratios were used to generate Z-scores in our cohort to compare 217 
differences in size of the fetal head and/or abdomen versus the femur. In contrast to a 218 
5% rate of microcephaly, a femur-sparing pattern of fetal growth restriction was 219 
observed after 34 weeks gestation in 37% (17/46) of pregnancies based on either a 220 
small head (HC:FL; 28%, 13/46) or abdomen (AC:FL; 20%, 9/46) in relation to the femur 221 
(Z-scores <-1.3; Fig. 1). If we considered ultrasound data from any time during 222 
pregnancy, 52% (29/56) of pregnancies had a differentially small head or abdomen in 223 
comparison to the femur [Z-scores <-1.3; HC:FL 39% (22/56) and/or AC:FL 30% 224 
(17/56); Fig. 1]; this final analysis allowed inclusion of fetuses from the second trimester 225 
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pregnancy terminations and the stillbirth and preterm birth cases. If we considered only 226 
women with symptomatic ZIKV infection, an abnormal HC:FL ratio was observed in 46% 227 
(6/13) and an abnormal AC:FL ratio in 15% (2/13). In pregnancies with an abnormal 228 
HC:FL or AC:FL ratio, the ratio became more skewed over time in most pregnancies 229 
(Fig. S1 and S2). Overall, the majority of pregnancies in our study with a possible 230 
maternal ZIKV infection developed a femur-sparing profile of growth restriction using 231 
fetal body ratios developed from the IG-21 sonographic standard. 232 
Comment 233 
Principal Findings of the Study 234 
Our study is the first to demonstrate a femur-sparing pattern of IUGR in late gestation of 235 
women with a possible ZIKV infection. This unusual fetal growth profile was found by 236 
application of the IG-21 and WHO-FGC standards and differs from prior models of 237 
IUGR (Fig. 2). We found a significant skewing of fetal biometrics with a smaller AC 238 
versus FL, which was first apparent in the 24-27 6/7 week strata. Fetal body ratios 239 
(HC:FL and AC:FL, by IG-21) were consistent with a femur-sparing pattern of fetal 240 
growth restriction in the majority of pregnancies with possible maternal ZIKV infection.  241 
Results in the Context of What is Known 242 
Fetuses that were either small for gestational age or growth restricted were reported to 243 
occur in 9% of pregnancies with a possible ZIKV infection in Rio de Janeiro, Brazil.[16] 244 
Interestingly, the authors characterized 4 cases of microcephaly in their cohort as either 245 
“proportionate” (2/4, 50%) or “disproportionate” (2/4, 50%) relative to the size of the 246 
infant; a “disproportionate” microcephaly indicated a grossly differential growth of the 247 
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head with respect to other body parts in at least half of their index cases. IUGR has also 248 
been described as a hallmark feature of several murine models of ZIKV infection in 249 
pregnancy and is associated with spontaneous abortion and stillbirth in these 250 
models.[41, 42, 43, 44] Although a femur-sparing pattern of growth restriction has been 251 
mentioned in the literature[45], it has not been characterized in the context of maternal 252 
complications of pregnancy or exposure to any teratogenic virus. Interestingly, few 253 
studies have characterized the IUGR phenotype in pregnancies with viral infections with 254 
the exception of a symmetric profile of IUGR associated with congenital 255 
cytomegalovirus infection.[13]  256 
Skewed Distribution of Fetal Biometry in Pregnancies with Possible Maternal 257 
ZIKV Infection 258 
Beginning in the late second trimester, maternal ZIKV infection was associated with a 259 
significantly smaller AC, by both IG-21 and WHO-FGC, and HC by IG-21 compared to 260 
FL. Analysis of IG-21 fetal body ratios with respect to FL revealed a femur-sparing 261 
profile of growth restriction in the majority of pregnancies with a possible ZIKV infection. 262 
The stable or negative trajectory of the AC:FL or HC:FL over time and the high 263 
proportion of women with symptoms (nearly half) with an abnormal HC:FL ratio is 264 
concerning for ZIKV-associated fetal injury. Identification of a femur-sparing profile of 265 
fetal growth restriction using IG-21 fetal body ratios could aid pediatricians in prioritizing 266 
neonates for imaging in low-resource settings. It is important to note that this profile of 267 
injury may not be obvious using other sonographic standards, primarily due to 268 
differences in FL distribution. For example, the Hadlock sonographic standard is 269 
anecdotally associated with the finding of “short femurs” and may not yield the same 270 
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growth restriction profile.[28, 29, 30] A discordance between the rate of fetuses with a 271 
small AC and rate of small for gestational age neonates may be a consequence of this 272 
particular type of growth restriction that preserves skeletal growth, which may 273 
compensate for birth weight. Whether abnormal growth of the fetus in relation to the 274 
femur correlates with long-term adverse outcomes for the developing child is unknown, 275 
but identification of an abnormal fetal body ratio (AC:FL or HC:FL) may be superior to 276 
measurement of fetal BPD or HC alone as a marker for ZIKV-associated fetal injury. 277 
Clinical and Research Implications 278 
The pathogenesis of perinatal infections resulting in fetal injury is complex and involves 279 
both indirect and direct effects. ZIKV infections could have a direct effect on fetal growth 280 
through targeted injury of the brain and liver, but also an indirect effect through 281 
trophoblast injury and a reduction in oxygen carrying capacity.[46] If viral tropism for 282 
cells in the fetal brain and liver is greater than tropism for the skeleton, this could 283 
produce differential viral effects on fetal growth that might result in the femur-sparing 284 
profile of fetal growth restriction that we observed in our study. As the size of the fetal 285 
abdomen directly correlates with liver size [47], ZIKV injury of the fetal liver may depress 286 
growth of the abdomen. ZIKV RNA has been detected in the liver in humans and animal 287 
models.[11, 48, 49] Liver injury is also a well-known outcome for many viruses related to 288 
ZIKV (e.g. Hepatitis C, dengue virus).[50, 51] Future studies of the effect of ZIKV on the 289 
fetal liver may in part explain the pathogenesis of fetal growth restriction with this 290 
infection. 291 
We would like to emphasize that our results do not suggest that a femur-sparing profile 292 
of growth restriction is the only possible phenotype or outcome of perinatal ZIKV 293 
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infection. A normal growth profile may occur if the pregnant woman clears the virus 294 
before vertical transmission can occur. A fetal growth profile consistent with symmetric 295 
IUGR may occur with early and severe placental infections, which could compromise 296 
placental function; this effect would be similar to observations of placental infarctions 297 
and compromised placental oxygen transport in a nonhuman primate model following 298 
experimental ZIKV infection.[46] Additional research may further elucidate the 299 
relationship between IUGR and ZIKV infection, and characterize extreme cases of fetal 300 
injury, phenotype of IUGR and impact of timing of infection. Finding a more sensitive 301 
biomarker of viral injury, such as a sonographic profile of fetal growth, may help guide 302 
the pediatricians’ evaluation and triage cases for postnatal follow up where resources 303 
are limited.  304 
Strengths and Weaknesses 305 
The strengths of this study are in the detailed fetal growth assessment from a relatively 306 
large sample of pregnancies with possible maternal ZIKV infection and the novel 307 
identification of a variant in fetal growth restriction associated with viral infection. A 308 
further strength is in the evaluation and comparison of biometric measures using two 309 
contemporary, international fetal growth studies. Finally, the novel use of IG-21 fetal 310 
body ratios to interpret fetal size in pregnancies with possible ZIKV infection may be 311 
useful for clinical care and also relevant to more common forms of IUGR. One limitation 312 
of our study is that the diagnosis of ZIKV infection is challenging due to the transient 313 
nature of viremia and cross-reactivity with other flaviviruses. Another important study 314 
limitation is the small sample size and lack of a specific fetal growth standard for this 315 
population; creating a robust standard would be challenging, however, given the ethnic 316 
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diversity of the cohort. Future studies with larger cohorts are necessary to validate our 317 
findings and determine if adverse neonatal outcomes might be associated with a femur-318 
sparing profile of growth restriction. Although our study definitions of IUGR and 319 
microcephaly were in line with current standards, they may capture some 320 
constitutionally small infants; as we did not base IUGR on EFW, this may also limit 321 
comparability to other studies. However, the surprising distribution of cases with 322 
differential growth of the abdomen and head versus the femur is suggestive of an 323 
unusual pattern of fetal growth restriction that is not typically seen in pregnancy.  324 
Conclusion 325 
In summary, our results suggest that infants born following a possible maternal ZIKV 326 
infection may have abnormal growth patterns of the fetal head and abdomen with 327 
respect to the femur. Calculation of IG-21 fetal body ratios (AC:FL or HC:FL) may 328 
provide an early indication of aberrant fetal growth before a clinical or sonographic 329 
diagnosis of IUGR or microcephaly. Alerting clinicians to deviations in symmetric growth 330 
of a nonmicrocephalic fetus with congenital ZIKV exposure may aid in the identification 331 
of cases at risk for a greater spectrum of ZIKV-associated morbidity (e.g. eye 332 
abnormalities, postnatal microcephaly). These cases could be prioritized for more 333 
intensive neonatal follow-up in low resource settings for earlier interventions after 334 
delivery. Ultimately, larger cohorts will be important to validate a femur-sparing profile of 335 
growth restriction in women with a possible ZIKV infection in pregnancy and investigate 336 
whether this profile might predict adverse fetal and neonatal outcomes.  337 
  338 
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Figure Legends 
Figure 1. Fetal Body Ratio Z-Scores from U.S. Women with Possible Maternal 
ZIKV Exposure Using the IG-21 Sonographic Standard. A negatively skewed 
distribution of HC:FL and AC:FL is apparent within every gestational age strata. 
Data is color coordinated to show individual subjects. Depending on the number 
of ultrasound scans per subject, one subject may contribute ultrasound data to 
multiple gestational age strata in the table, but only one (the latest) ultrasound 
per subject was used in each strata. Application of the IG-21 sonographic 
standard to generate Z-scores is shown for HC:FL (A), and AC:FL (B).  
 
Figure 2. Femur-sparing Profile of IUGR in Comparison to Normal and Other 
Abnormal Fetal Growth Patterns. Aberrant fetal growth in association with a 
possible maternal ZIKV infection is characterized by a femur-sparing profile of 
aberrant fetal growth. This figure illustrates how the femur-sparing profile of 
IUGR compares to normal fetal growth and more common IUGR growth patterns 
(symmetric and asymmetric IUGR). 
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Table 1. Rates of Microcephaly and IUGR by Exposure Time 
 
Exposure Time 
Gestational 
Age at 
Delivery 
(weeks) 
Prenatal Diagnosis of 
Microcephaly (HC <3%) Prenatal Diagnosis of IUGR 
Birthweight*
(g) 
 
 
Birthweight 
(% IG-21) WHO-FGC IG-21 
AC <3% AC <10% 
WHO-
FGC IG-21 
WHO-
FGC IG-21 
All (N=56) 37.4 (4.2) 3 (5) 3 (5) 5 (9) 5 (9) 8 (14) 10 (18) 3159 (659) 55 (28.9) 
Preconception 
(N=4) 38 (0) 0 0 0 0 1 (25) 1 (25) 2682 (102) 
18.4 (3.3) 
First Trimester 
(N=16) 39.1 (0.8) 1 (6) 1 (6) 3 (19) 2 (13) 3 (19) 5 (31) 3324 (328) 
60.2 (22.1) 
Second 
Trimester 
(N=11) 
37.8 (3.2) 1 (9) 1 (9) 1 (9) 1 (9) 1 (9) 1 (9) 3412 (524) 
59.0 (36.8) 
Unknown 
Trimester 
(N=25) 
38.2 (2.2) 1 (4) 1 (4) 1 (4) 2 (8) 3 (12) 3 (12) 3111 (676) 
54.3 (29.5) 
 
Numbers reflect the mean (standard deviation) or N (%) with Z-score (as indicated) for the entire cohort and also by time 
of possible ZIKV exposure. Data for prenatal diagnosis of microcephaly and IUGR is based on the last ultrasound 
obtained per subject. AC, abdominal circumference; FL, femur length; HC, head circumference; IG-21, 2014 International 
Fetal and Newborn Growth Consortium for the 21st Century; WHO-FGC, World Health Organization Fetal Growth Chart 
study. *Birthweight data was available for 48 infants (preconception, N=2; first trimester, N=15; second trimester, N=8; 
unknown trimester, N=23). 
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Table 2. IG-21 Fetal Z-Scores for Biometric Measures by Gestational Age Strata 
Gestational Age 
Strata 
HC AC FL P values 
FL vs. HC FL vs. AC 
All  
(N=56) 
0.1 (1.2) 0.0 (1.3) 0.7 (1.4) <0.001 <0.001 
>34 weeks  
(N= 46) 
0.4 (0.6) 0.2 (0.8) 0.9 (0.9) <0.001 <0.001 
28 – 33 6/7 weeks 
(N= 38) 
0.1 (1.4) 0.1 (1.4) 0.7 (1.4) 0.007 <0.001 
24 – 27 6/7 weeks  
(N= 17) 
0.5 (0.7) -0.1 (0.7) 0.6 (0.8)  0.8 0.002 
18-23 6/7 weeks  
(N= 19) 
0.2 (1.3) 0.0 (1.5) 0.5 (1.2) 0.9 0.7 
 
Values reflect Z-scores within each gestational age strata using the last US scan 
in each pregnancy or gestational age strata based on the number of subjects. 
HC, head circumference; AC, abdominal circumference; FL, femur length. P 
values were calculated using Wilcoxon rank sum to compare paired Z-scores 
(IG-21) between FL and HC or FL and AC. A p value of <0.05 was considered 
significant.  
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Tables 
Table S1. Values for BPD:FL Mean and Standard Deviation Derived from IG-21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values represent the mean, mean ± 1 or mean ±2 standard deviations for BPD:FL ratio 
for each gestational week as derived from the IG-21 sonographic standard. IG-21 Z-
scores for fetal body ratios, biometric measures and neonatal head circumference are 
publicly accessible on the web.(1) 
Gestational 
Age 
Mean 
-2 SD 
Mean 
-1 SD 
Mean 
BPD:FL 
Mean 
+1 SD 
Mean 
+2 SD 
15 1.68 1.83 1.97 2.12 2.26 
16 1.57 1.70 1.83 1.97 2.10 
17 1.48 1.61 1.73 1.86 1.98 
18 1.42 1.54 1.66 1.77 1.89 
19 1.38 1.49 1.60 1.71 1.82 
20 1.34 1.45 1.55 1.66 1.76 
21 1.32 1.42 1.52 1.62 1.72 
22 1.30 1.40 1.50 1.59 1.69 
23 1.29 1.39 1.48 1.57 1.66 
24 1.29 1.38 1.47 1.55 1.64 
25 1.28 1.37 1.45 1.54 1.63 
26 1.28 1.36 1.45 1.53 1.62 
27 1.28 1.36 1.44 1.52 1.60 
28 1.27 1.35 1.43 1.51 1.60 
29 1.27 1.35 1.43 1.51 1.59 
30 1.27 1.35 1.42 1.50 1.58 
31 1.27 1.34 1.42 1.49 1.57 
32 1.26 1.34 1.41 1.49 1.56 
33 1.26 1.33 1.41 1.48 1.55 
34 1.25 1.33 1.40 1.47 1.54 
35 1.25 1.32 1.39 1.46 1.53 
36 1.24 1.31 1.38 1.45 1.52 
37 1.23 1.30 1.37 1.44 1.51 
38 1.22 1.29 1.36 1.42 1.49 
39 1.21 1.27 1.34 1.41 1.48 
40 1.19 1.26 1.33 1.39 1.46 
41 1.18 1.25 1.31 1.38 1.45 
42 1.16 1.23 1.30 1.36 1.43 
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Table S2. Values for HC:FL Mean and Standard Deviation Derived from IG-21 
 
Gestational 
Age 
Mean 
-2 SD 
Mean 
-1 SD 
Mean 
HC:FL 
Mean 
+1 SD 
Mean 
+2 SD 
15 5.98 6.43 6.87 7.32 7.76 
16 5.59 6.00 6.41 6.82 7.23 
17 5.30 5.69 6.07 6.45 6.83 
18 5.11 5.46 5.82 6.18 6.54 
19 4.97 5.30 5.64 5.98 6.32 
20 4.87 5.19 5.51 5.83 6.15 
21 4.80 5.11 5.41 5.72 6.03 
22 4.75 5.04 5.34 5.63 5.93 
23 4.72 5.00 5.28 5.57 5.85 
24 4.69 4.97 5.24 5.51 5.78 
25 4.67 4.94 5.20 5.47 5.73 
26 4.66 4.91 5.17 5.43 5.68 
27 4.64 4.89 5.14 5.39 5.64 
28 4.63 4.87 5.11 5.36 5.60 
29 4.61 4.85 5.09 5.33 5.56 
30 4.59 4.83 5.06 5.29 5.53 
31 4.57 4.80 5.03 5.26 5.49 
32 4.55 4.77 5.00 5.22 5.45 
33 4.52 4.74 4.96 5.18 5.40 
34 4.49 4.71 4.92 5.14 5.36 
35 4.45 4.67 4.88 5.10 5.31 
36 4.42 4.63 4.84 5.05 5.26 
37 4.38 4.59 4.80 5.00 5.21 
38 4.33 4.54 4.75 4.95 5.16 
39 4.29 4.49 4.70 4.90 5.10 
40 4.24 4.44 4.64 4.84 5.05 
41 4.18 4.39 4.59 4.79 4.99 
42 4.13 4.33 4.53 4.73 4.93 
 
Values represent the mean, mean ± 1 or mean ± 2 standard deviations for HC:FL ratio 
for each gestational week as derived from the IG-21 sonographic standard. IG-21 Z-
scores for fetal body ratios, biometric measures and neonatal head circumference are 
publicly accessible on the web.(1) 
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Table S3. Values for AC:FL Mean and Standard Deviation Derived from IG-21 
 
Gestational 
Age 
Mean 
-2 SD 
Mean 
-1 SD 
Mean 
AC:FL 
Mean 
+1 SD 
Mean 
+2 SD 
15 4.92 5.31 5.70 6.10 6.49 
16 4.68 5.05 5.42 5.79 6.16 
17 4.49 4.84 5.20 5.55 5.90 
18 4.35 4.69 5.03 5.37 5.71 
19 4.25 4.57 4.90 5.23 5.56 
20 4.17 4.49 4.81 5.12 5.44 
21 4.12 4.43 4.74 5.04 5.35 
22 4.08 4.38 4.68 4.99 5.29 
23 4.06 4.35 4.65 4.94 5.24 
24 4.05 4.34 4.63 4.92 5.20 
25 4.05 4.33 4.61 4.90 5.18 
26 4.05 4.33 4.61 4.89 5.17 
27 4.06 4.33 4.61 4.88 5.16 
28 4.07 4.35 4.62 4.89 5.16 
29 4.09 4.36 4.63 4.90 5.16 
30 4.11 4.38 4.64 4.91 5.17 
31 4.14 4.40 4.66 4.92 5.19 
32 4.16 4.42 4.68 4.94 5.20 
33 4.19 4.44 4.70 4.96 5.22 
34 4.21 4.47 4.73 4.98 5.24 
35 4.24 4.50 4.75 5.00 5.26 
36 4.27 4.52 4.77 5.03 5.28 
37 4.30 4.55 4.80 5.05 5.30 
38 4.33 4.58 4.83 5.08 5.33 
39 4.36 4.61 4.85 5.10 5.35 
40 4.39 4.63 4.88 5.13 5.38 
41 4.42 4.66 4.91 5.15 5.40 
42 4.45 4.69 4.94 5.18 5.43 
 
Values represent the mean, mean ± 1 or mean ± 2 standard deviations for AC:FL ratio 
for each gestational week as derived from the IG-21 sonographic standard. IG-21 Z-
scores for fetal body ratios, biometric measures and neonatal head circumference are 
publicly accessible on the web.(1)
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Table S4. Laboratory Evidence for Possible Maternal ZIKV Infection 
 
Subject Symptom Serum PCR Urine PCR 
Zika 
IgM #1 
Zika 
IgM 
#2 
Zika 
PRNT #1 
Zika 
PRNT 
#2 
Infant 
Serum 
PCR 
Infant 
Urine 
PCR 
Infant 
IgM 
First Trimester Exposure 
1 None Pos Neg Pos Not Done Not Done 
Not 
Done 
Not 
Done 
Not 
Done 
Not 
Done 
2 Yes-rash Neg Not Done Pos Not Done Pos* 
Not 
Done Neg Neg Neg** 
3 None Pos Neg Pos Not Done Pos* 
Not 
Done Neg Neg Neg 
4 None Neg Neg Pos Neg Pos Not Done Neg Neg Neg 
5 None Pos Neg Pos Not Done Not Done 
Not 
Done Neg Neg Equiv 
6 None Neg Neg Pos Equiv Pos* Pos Neg Neg Equiv 
7 None Neg Pos Pos Not Done Pos* 
Not 
Done Neg Neg Equiv 
8 None Neg Neg Pos Neg Pos Not Done Neg Neg Neg 
9 None Not Done Not Done Pos Pos Pos* Not Done 
Not 
Done 
Not 
Done 
Not 
Done 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Subject Symptom Serum PCR Urine PCR 
Zika 
IgM #1 
Zika 
IgM 
#2 
Zika 
PRNT #1 
Zika 
PRNT 
#2 
Infant 
Serum 
PCR 
Infant 
Urine 
PCR 
Infant 
IgM 
First Trimester Exposure (Cont’d) 
10 Yes-arthralgia Not Done Not Done Pos Neg Pos* Not Done 
Not 
Done 
Not 
Done 
Not 
Done 
11 None Equiv Neg Pos Neg Pos* Not Done 
Not 
Done 
Not 
Done 
Not 
Done 
12 None Pos Not Done Neg Not Done Not Done 
Not 
Done Neg Neg Neg 
13 Yes - rash, fever Equiv Neg Pos Pos Pos* Pos* 
Not 
Done 
Not 
Done 
Not 
Done 
14 Yes - rash, 
arthralgia Not Done Not Done Pos Equiv Pos* Pos* 
Not 
Done 
Not 
Done 
Not 
Done 
15 
Yes-fever, 
rash, 
arthralgia 
Pos Not Done Neg Not Done Not Done 
Not 
Done 
Not 
Done 
Not 
Done 
Not 
Done 
16 Yes-rash Pos Not Done Pos Not Done Not Done 
Not 
Done Neg 
Not 
Done Neg 
Second Trimester Exposure 
17 No Not Done Not Done Pos Pos Pos* Not Done Neg 
Not 
Done Neg 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Subject Symptom Serum PCR Urine PCR 
Zika 
IgM #1 
Zika 
IgM 
#2 
Zika 
PRNT #1 
Zika 
PRNT 
#2 
Infant 
Serum 
PCR 
Infant 
Urine 
PCR 
Infant 
IgM 
Second Trimester Exposure (Cont’d) 
18 
Yes - rash, 
fever, 
headache 
Not Done Not Done Pos Not Done Pos* 
Not 
Done Neg Neg Neg 
19 
Yes - rash, 
headache, 
conjunctivitis 
Pos Pos Pos Not Done Not Done 
Not 
Done Neg Neg Neg 
20 No Neg Neg Equiv Equiv Pos* Not Done Neg Neg Neg 
21 Yes- rash Pos Pos Pos Not Done Pos* 
Not 
Done Neg 
Not 
Done Neg 
22 Yes – rash Neg Neg Pos Not Done Pos* 
Not 
Done 
Not 
Done 
Not 
Done Neg 
23 No Not Done Neg Pos Equiv Pos* Pos* Neg Neg Equiv 
24 Yes – rash Neg Neg Pos Not Done Pos* 
Not 
Done Neg 
Not 
Done Equiv 
25 Yes – rash Neg Neg Pos Pos Pos* Pos* Neg Not Done Equiv 
26 Yes - fever, 
myalgias, rash Neg Neg Neg Neg Pos* 
Not 
Done 
Not 
Done 
Not 
Done 
Not 
Done 
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Subject Symptom Serum PCR Urine PCR 
Zika 
IgM #1 
Zika 
IgM 
#2 
Zika 
PRNT #1 
Zika 
PRNT 
#2 
Infant 
Serum 
PCR 
Infant 
Urine 
PCR 
Infant 
IgM 
Unknown Trimester Exposure 
27 None Pos Neg Neg Not Done Not Done 
Not 
Done Neg Neg Neg** 
28 None Neg Neg Pos Pos Pos* Pos* Neg Not Done Neg** 
29 None Not Done Not Done Pos Not Done Pos* 
Not 
Done 
Not 
Done 
Not 
Done 
Not 
Done 
30 None Neg Pos Pos Not Done Not Done 
Not 
Done Neg Neg Equiv 
31 None Neg Neg Equiv Not Done Pos* 
Not 
Done 
Not 
Done 
Not 
Done 
Not 
Done 
32 None Neg Neg Equiv Pos Pos* Pos* Neg Neg Equiv 
33 None Neg Neg Pos Pos Pos* Not Done Neg Neg Pos 
34 None Neg Neg Pos Neg Pos* Not Done Neg 
Not 
Done Equiv 
35 None Neg Neg Pos Equiv Pos* Not Done 
Not 
Done Neg Equiv 
36 None Neg Neg Equiv Not Done Pos* 
Not 
Done Neg Neg Equiv 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Subject Symptom Serum PCR Urine PCR 
Zika 
IgM #1 
Zika 
IgM 
#2 
Zika 
PRNT #1 
Zika 
PRNT 
#2 
Infant 
Serum 
PCR 
Infant 
Urine 
PCR 
Infant 
IgM 
Unknown Trimester Exposure (Cont’d) 
37 None Neg Neg Pos Pos Pos* Not Done Neg Neg Equiv 
38 None Neg Neg Pos Not Done Pos* 
Not 
Done 
Not 
Done Neg Neg 
39 None Neg Neg Pos Neg Pos* Pos* Neg Neg Equiv 
40 None Neg Neg Pos Not Done Pos* 
Not 
Done Neg Neg Equiv 
41 None Neg Pos Pos Not Done Not Done 
Not 
Done Neg 
Not 
Done Neg 
42 None Neg Pos Pos Neg Pos* Not Done Neg Neg Neg 
43 None Neg Neg Pos Neg Pos* Not Done Neg Neg Neg 
44 None Neg Neg Pos Pos Pos* Not Done 
Not 
Done Neg Equiv 
45 None Pos Neg Neg Not Done Not Done 
Not 
Done Neg Neg Neg 
46 None Neg Neg Pos Neg Pos* Not Done Neg Neg 
Not 
Done 
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Subject Symptom Serum PCR Urine PCR 
Zika 
IgM #1 
Zika 
IgM 
#2 
Zika 
PRNT #1 
Zika 
PRNT 
#2 
Infant 
Serum 
PCR 
Infant 
Urine 
PCR 
Infant 
IgM 
Unknown Trimester Exposure (Cont’d) 
47 None Neg Neg Equiv Neg Pos Not Done 
Not 
Done 
Not 
Done Neg 
48 None Not Done Not Done Not Done 
Not 
Done Pos* 
Not 
Done Neg 
Not 
Done Neg 
49 None Neg Neg Pos Not Done Pos* 
Not 
Done Neg Neg Neg 
50 None Neg Neg Pos Not Done Pos* 
Not 
Done 
Not 
Done 
Not 
Done 
Not 
Done 
51 None Neg Neg Equiv Not Done Pos* 
Not 
Done 
Not 
Done 
Not 
Done 
Not 
Done 
Preconception Exposure 
52 None Neg Neg Pos Not Done Pos* 
Not 
Done 
Not 
Done Neg Equiv 
53 None Neg Neg Equiv Neg Pos* Pos* Neg Not Done Neg 
54 None Neg Neg Equiv Not Done Pos* 
Not 
Done 
Not 
Done 
Not 
Done 
Not 
Done 
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Subject Symptom Serum PCR Urine PCR 
Zika 
IgM #1 
Zika 
IgM 
#2 
Zika 
PRNT #1 
Zika 
PRNT 
#2 
Infant 
Serum 
PCR 
Infant 
Urine 
PCR 
Infant 
IgM 
Preconception Exposure (Cont’d) 
55 None Neg Neg Pos Neg Pos* Pos* Not Done 
Not 
Done 
Not 
Done 
56 None Neg Neg Equiv Not Done Pos* 
Not 
Done 
Not 
Done 
Not 
Done 
Not 
Done 
 
Pos, positive; Neg, negative; Equiv, equivocal test result. 
*Refers to a positive test result for an “undifferentiated flavivirus.”  
**Negative ZIKV IgM result, but a West Nile Virus microsphere immunoassay positive. Positive results are known to occur 
with persons vaccinated or infected with other flaviviruses, like ZIKV. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table S5. Fetal Biometric Measures Less than the 3rd Centile  
 
Gestational Age 
Groups 
HC (<3%) AC (<3%) FL (<3%) 
WHO-
FGC 
IG-21 WHO-
FGC 
IG-21 WHO-
FGC 
IG-21 
All  
(N=56) 
3 (5) 3 (5) 3 (5) 3 (5) 5 (9) 4 (7) 
>34 weeks  
(N= 46) 
0 0 1 (2) 2 (4) 2 (4) 1 (2) 
28 – 33 6/7 weeks 
(N= 38) 
2 (5) 2 (5) 1 (3) 2 (5) 2 (5) 3 (8) 
24 – 27 6/7 weeks  
(N= 17) 
0 0 0 0 0 0 
18-23 6/7 weeks  
(N= 19) 
1 (5) 1 (5) 1 (5) 1 (5) 1 (5) 1 (5) 
 
Values reflect N (%) less than the 3rd centile within each gestational age strata using the 
last US scan in each pregnancy or gestational age strata based on the number of 
subjects. HC, head circumference; AC, abdominal circumference; FL, femur length. 
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Table S6. Birth Outcomes for Each Subject 
 
Subject 
Gestational Age 
at Delivery 
(weeks) 
Birthweight
(g) 
Birthweight 
Z-score  
IG-21 
HC at 
birth 
(cm) 
HC Z-
score 
IG-21 
Postnatal 
Imaging 
Delivery 
Outcome 
First Trimester Exposure 
1 19 - - - - - 
D+E, 
Placenta 
PCR+ 
2 33 1320 -1.5 27.5 -2.1 Normal PTD@33 
weeks 
3 40 3450 0.5 34.5 0.7 Normal Term 
4 36 2640 0.1 34 1.5 Not Done PTD@36 
weeks 
5 39 3105 -0.3 35 0.9 Normal Term 
6 37 3135 0.6 32 -0.8 Normal Term 
7 39 3190 0.2 33 -0.4 Normal Term 
8 40 2930 -0.9 33 -0.7 Normal Term 
9 - - - - - - D+E 
10 40 3680 0.7 34 -0.3 Normal Term 
11 40 3480 0.5 34 0.2 Not Done Term 
12 40 3165 -0.3 34.5 0.7 Normal Term 
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Subject 
Gestational Age 
at Delivery 
(weeks) 
Birthweight
(g) 
Birthweight 
Z-score  
IG-21 
HC at 
birth 
(cm) 
HC Z-
score 
IG-21 
Postnatal 
Imaging 
Delivery 
Outcome 
First Trimester Exposure (Cont’d) 
13 39 3440 0.8 - - Not Done Term 
14 39 3425 0.7 34 0.5 Normal Term 
15 23 - - - - - D+E 
16 39 2850 -0.7 33.5 0.1 Normal Term 
Second Trimester Exposure 
17 39 2800 -1.1 33.5 -0.3 Not Done Term 
18 40 3860 1.1 34 -0.3 Normal Term 
19 39 3380 0.3 36 1.7 Normal Term 
20 39 3395 0.4 34.5 0.5 Normal Term 
21 40 3565 0.4 35 0.6 Normal Term 
22 37 2630 -0.7 34.5 1.2 Left CPC Term 
23 38 3315 0.6 34 0.4 Right CPC Term 
24 39 2970 -0.7 34 0.1 Normal Term 
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Subject 
Gestational Age 
at Delivery 
(weeks) 
Birthweight
(g) 
Birthweight 
Z-score  
IG-21 
HC at 
birth 
(cm) 
HC Z-
score 
IG-21 
Postnatal 
Imaging 
Delivery 
Outcome 
Second Trimester Exposure (Cont’d) 
25 40 3760 0.9 35 0.6 Normal Term 
26 30 725 -3.0 - - - 
IUFD @30 
weeks, 
Placenta 
PCR+ 
Unknown Trimester Exposure 
27 37 2100 -2.0 32.5 -0.4 Normal 
IUGR, 
Hypotonia, 
Prader-Willi 
28 35 2815 0.8 33.5 1.1 Not Done PTD@35 
weeks 
29 40 2855 -1.3 34 -0.3 Not Done Term 
30 40 3685 0.7 34.5 0.2 Normal Term 
31 39 2975 -0.4 33.5 0.1 Not Done Term 
32 39 3155 -0.2 34.5 0.5 Normal Term 
33 39 3285 0.4 33.5 0.1 Normal Term 
34 39 3275 0.4 34.5 1.0 Left CPC Term 
35 37 3690 2.1 34 1.2 Not Done Term 
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Subject 
Gestational Age 
at Delivery 
(weeks) 
Birthweight
(g) 
Birthweight 
Z-score  
IG-21 
HC at 
birth 
(cm) 
HC Z-
score 
IG-21 
Postnatal 
Imaging 
(First Week 
of Life) 
Delivery 
Outcome 
Unknown Trimester Exposure (Cont’d) 
36 40 3700 0.8 35 0.6 Grade 1 IVH Term 
37 38 3650 1.6 35 1.7 Normal Term 
38 33 1859 -0.2 29 -1.4 Normal PTD@33 
weeks 
39 38 2990 -0.2 34 0.4 Normal Term 
40 37 3130 0.8 34.5 1.6 Normal Term 
41 39 3420 0.4 34.5 0.5 Not Done Term 
42 39 3135 0.0 34 0.5 Normal Term 
43 40 3840 1.1 34 -0.3 Normal Term 
44 39 3845 1.7 35.5 1.8 Normal Term 
45 41 3940 2.0 37 2.0 Not Done Term 
46 39 4290 2.3 36 1.7 Normal Term 
47 40 3060 -0.8 34.5 0.2 Normal Term 
48 38 2985 0.03 34 0.8 Normal Term 
49 38 3790 1.6 34 0.4 Normal Term 
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Subject 
Gestational Age 
at Delivery 
(weeks) 
Birthweight 
(g) 
Birthweight 
Z-score  
IG-21 
HC at 
birth 
(cm) 
HC Z-
score 
IG-21 
Postnatal 
Imaging 
Delivery 
Outcome 
Unknown Trimester Exposure (Cont’d) 
50 - - - - - - - 
51 40 3305 -0.2 35 0.6 Not Done Term 
Preconception Exposure 
52 38 2610 -1.0 33 0 Normal Term 
53 39 2755 -0.8 33 -0.4 Normal Term 
54 38 - - - - - - 
55 - - - - - - - 
56 - - - - - - - 
 
-, Information not available. 
D+E, second trimester termination of pregnancy with or without prior fetal demise,  
PTD, preterm delivery 
CPC, choroid plexus cyst 
IUFD, intrauterine fetal demise  
Postnatal imaging reflects a neonatal head US performed within the first week of life. 
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Table S7. Distribution and Comparison of Fetal Biometric Measures by WHO-FGC 
 
Gestational Age 
Groups 
HC AC FL P values 
 
FL vs. HC 
 
FL vs. AC 
All  
(N=56) 
54 (24) 49 (29) 59 (28) 0.6 <0.001 
>34 weeks  
(N= 46) 
57 (19) 53(26) 63 (25) 0.4 0.05 
28 – 33 6/7 weeks 
(N= 38) 
59 (26) 55 (29) 64 (30) 0.07 0.004 
24 – 27 6/7 weeks  
(N= 17) 
67 (23) 39 (25) 63 (28) 0.3 0.001 
18-23 6/7 weeks  
(N= 19) 
68 (28) 60 (30) 70 (25) 0.08 1 
 
Values reflect Mean (SD) within each gestational age strata using the last US scan in 
each pregnancy or gestational age strata based on the number of subjects. HC, head 
circumference; AC, abdominal circumference; FL, femur length. The p values were 
calculated using Wilcoxon rank sum to compare percentiles determined by WHO-FGC 
between HC and FL or AC and FL. A p value of <0.05 was considered significant.  
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Figure S1. HC:FL Ratio Across Gestational Age in Subjects with a Ratio Z-Score 
Less than 10th Centile 
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Figure S2. AC:FL Ratio Across Gestational Age in Subjects with a Ratio Z-Score 
Less than 10th Centile 
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